Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02936232
Other study ID # 1408-003-599
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 2014
Est. completion date March 2028

Study information

Verified date November 2023
Source Seoul National University Hospital
Contact Kyung Su Kim, MD, PhD
Phone 82-10-8033-1127
Email kanesu@gmail.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The aim of this study is to construct multi-center sepsis registry that can be used for data warehousing and clinical research.


Description:

This registry prospectively enrolls adult patients with severe sepsis or septic shock in 21 tertiary hospital emergency departments. Registered data can be used for quality control and clinical research to reduce sepsis-related mortality.


Recruitment information / eligibility

Status Recruiting
Enrollment 3000
Est. completion date March 2028
Est. primary completion date March 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - two of more systemic inflammatory reaction syndrome criteria fever > 38.3 'C or hypothermia < 36'C, tachycardia over 90 bpm tachypnea over 20 per minute, leukocytosis (WBC over 12k/microL) or leukopenia (WBC below 4k/microL) - suspected or proven infection - any organ dysfunction as follows: 1. cardiovascular (hypotension, systolic blood pressure <90 mmHg, mean arterial pressure <70mmHg) 2. tissue hypoperfusion (lactate above upper limits laboratory normal) 3. acute lung injury (PaO2/inspired oxygen fraction < 250 in the absence of pneumonia, PaO2/inspired oxygen fraction < 200 in the presence of pneumonia) 4. acute kidney injury (Urine output < 0.5mL/kg/hr for at least 2 hrs Serum creatinine > 2.0 mg/dL) 5. acute liver injury (Total bilirubin > 2mg/dL) 6. acute coagulopathy (Platelet count < 100,000/µL or prothrombin time, international normalized ratio > 1.5) Exclusion Criteria: - age less than 18 years old - patients with cardiac arrest at presentation - patients with advanced directives not to deliver aggressive organ supportive management

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Korea, Republic of Seoul National University Bundang Hospital Seongnam-si Gyeonggi-do
Korea, Republic of Seoul Metropolitan Government-Seoul National University Boramae Medical Center Seoul
Korea, Republic of Seoul National University Hospital Seoul

Sponsors (22)

Lead Sponsor Collaborator
Seoul National University Hospital Asan Medical Center, Bucheon St. Mary's Hospital, Chonbuk National University Hospital, Chonnam National University Hospital, Chosun University Hospital, Gangnam Severance Hospital, Hallym University Kangnam Sacred Heart Hospital, Hallym University Medical Center, Hanyang University Seoul Hospital, Inje University Ilsan Paik Hospital, Jeju National University Hospital, Korea University Anam Hospital, Korea University Guro Hospital, Kyunghee University Medical Center, Kyungpook National University Hospital, Samsung Medical Center, Seoul National University Boramae Hospital, Seoul National University Bundang Hospital, Severance Hospital, The Catholic University of Korea, Ulsan University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary 28-day mortality According to hospital discharge record review and telephone follow-up. 28-day
Secondary 90-day mortality According to hospital discharge record review and telephone follow-up. 90-day
Secondary Organ support treatment (mechanical ventilation) According to hospital record review hospital discharge (non-survivors) or 90 days (survivors)
Secondary Organ support treatment (renal replacement therapy) According to hospital record review hospital discharge (non-survivors) or 90 days (survivors)
Secondary ICU length of stay According to hospital record review hospital discharge (non-survivors) or 90 days (survivors)
Secondary Hospital length of stay According to hospital record review hospital discharge (non-survivors) or 90 days (survivors)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3